at the national and acute health care facility level
Chapter 8, Prison and Health, published
Guidelines
Key Populations
Recommended actions at international and national levels
2016 Update
Key population
SIAPS Technical Report. This report summarizes key accomplishments and lessons learned in implementing SIAPS’ approach to improving IPC practices in four countries: South Africa, Namibia, Jordan, and Ethiopia. All activities address SIAPS’s overall objective to build or enhance national and faci...lity capacity to develop, implement, and monitor IPC programs by focusing on the principles of health systems strengthening.
more
EBioMedicine. 2016 Jun 16. pii: S2352-3964(16)30276-6. doi: 10.1016/j.ebiom.2016.06.020. Open Access
Regional Tuberculosis Program, Pan American Health Organization (PAHO/WHO)
Legislative and Policy analysis and recommendations for reform
Petersen et al. Int J Ment Health Syst (2016) 10:30 DOI 10.1186/s13033-016-0060-z
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released i...n 2018 on diagnosing, preventing, and managing cryptococcal disease. In response to important new evidence that became available in 2021, these new guidelines strongly recommend a single high dose of liposomal amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV. This simplified regimen - a single high dose of liposomal amphotericin B paired with other standard medicines (flucytosine and fluconazole) - is as effective as the previous WHO standard of care, with the benefits of lower toxicity and fewer monitoring demands.
The objective of these guidelines is to provide updated, evidence-informed recommendations for treating adults, adolescents and children living with HIV who have cryptococcal disease. These guidelines are aimed at HIV programme managers, policymakers, national treatment advisory boards, implementing partners and health-care professionals providing care for people living with HIV in resource-limited settings with a high burden of cryptococcal disease.
more
Guidance issued as of 25 March 2020
This guidance is intended for use by health authorities to guide the actions taken by health-care providers for refugees and migrants in relation to the novel coronavirus (COVID-19) outbreak. This document is intended to address the needs and rights of refugees a...nd migrants living in all types of setting.
General recommendations made by WHO in the COVID-19 response (link here) are the superseding guidelines. Unfounded measures regarding testing, health screening and quarantine should not be imposed on refugees and migrants.
more
Guidelines for the development and implementation of institution-specific protection concepts
In order to help Member States understand what commercial foods for infants and young children are currently on the market, and to support implementation of the Guidance on ending inappropriate promotion of foods for infants and young children at the European level, the WHO Regional Office for Europ...e developed a methodology for identifying commercial baby foods available in retail settings and collecting data on their nutritional content, as well as various aspects of their packaging, labelling and promotion.
more
There is an urgent need to build Research and Development (R&D) capacity for leishmaniasis and other neglected tropical diseases (NTDs) in the Middle East and North Africa. The neglected tropical diseases are a group of 17 viral, bacterial, protozoan, and helminthic infections that often have high m...orbidity but low mortality, causing disabilities through their impact on child development and education, pregnancy outcomes, and worker productivity.
more